Our multidisciplinary Team, led by professionals with a long track record in drug development and management, relies on highly skilled personnel with unique competence in developing integrated solutions.
Lew Amsel is NLS’ head of pharmaceutical technology. Lew has extensive experience in the development of controlled release products (both solid and liquid), tablets, capsules, OTC products. As former vice-president, pharmaceutical technology at Watson Pharmaceutcal (now Actavis) he led the corporate pharmaceutical technology organization of one of the largest US generic manufacturers. Lew holds a Ph.D in pharmacy from the State University of New York at Buffalo.
CMC Regulatory Affairs Expert
Lorien is NLS’ CMC RA expert. Lorien has extensive experience within CMC regulatory affairs, research & development and quality assurance. Her experience encompasses multiple dosage forms including complex products, such as modified and extended release solid-oral, sterile and biologics. She holds a B.S. in chemistry from the University of North Carolina at Chapel Hill.
Research and Development
Bruno Figadère is NLS’s head of research and development and co-founder of the company. Bruno is an expert in chemistry more specifically in the design, isolation and synthesis of biomolecules. He is also a director and head of chemical research at the world-reknown National Center for Scientific Research in Paris - CNRS. He has 151 peer-reviewed publications with an h-index of 30 and holds a Ph.D. in chemistry from UPMC/Paris.
M&A and Business Development
Hervé is responsible for M&A and Business Development at NLS Pharma. He brings more than 15 years of experience in the Pharma and biotech industry, including ten years at Novartis AG as Global Head of M&A Novartis Consumer Health and then Global Head Novartis Pharma Out-Licensing and Partnering. Hervé holds a MBA from Columbia Business School and an Executive Business Leadership degree from Harvard Business School.
Chief Medical Officer
Nelson M. Handal, MD is NLS’s Chief Medical Officer. Nelson joined the group in August 2016. He has been primary investigator in over 50 clinical trials. Nelson trained as a General Psychiatrist at University of New York Health Science Center in Syracuse, NY and as a Child and Adolescent Psychiatrist at University of Miami School of Medicine in Miami, FL. He is Board Certified and a Distinguished Fellow of the American Psychiatric Association.
James R. Herman
Jim is NLS’ head of non-clinical drug safety. Jim has a broad expertise in pharmaceutical non-clinical safety discipline and drug development program design and execution. He is the former executive director of drug safety R&D at Pfizer Global Research and Development. He holds a doctor of philosophy, from the Environmental Toxicology Center at the University of Wisconsin-Madison.
Sharon Keys is NLS’ head of regulatory affairs. Sharon has extensive and in-depth experience in product development and market support. Prior to NLS she served as senior vice president R&D product strategy and global regulatory affairs at Shire Pharmaceuticals, the world’s leading AD-HD player. She holds a 1st class honours B.Sc. in physics and biology from the university of Ulster.
Eric Konofal is NLS’ head of drug discovery and co-founder of the company.
Eric joined the group in August 2015 and was appointed to the NLS Pharma Board of Directors in December 2015. He is a well known medical opinion leader in the field of child psychopathology and adolescent and pediatric sleep disorders. He’s involved in clinical research since 1999 and has published over 50 peer-reviewed papers and is an expert consultant for the French National Agency of Medicine and Health Products (ANSM) and for the European Medicines Agency (EMA). Eric received his M.D. and Ph.D. from UCMP/Paris and is a board certified neurologist.
Christian Wenger is NLS’ general counsel and partner at Wenger & Vieli Swiss law firm. Christian specializes in commercial and business law, with a focus on private equity, venture capital and mergers & acquisitions. He serves as chairman and member of various boards of directors of Swiss and international companies. He also is a member of the Executive Committee of SECA (Swiss Private Equity & Corporate Finance Association) and of the committee Venture Capital and Seed. He obtained his doctorate degree from the University of Zurich and completed his academic career with graduate studies at Duke University Law School in North Carolina (LL.M.).
Chief Executive Officer
Alex Zwyer is NLS’s chief executive officer and co-founder of the company.
Alex joined the group in August 2015 and was appointed to the NLS Pharma Board of Directors in December 2015. He was the former executive vice president globally responsible for marketing and sales, regulatory and medical affairs of Viforpharma, a world-leader in the treatment of iron deficiency, a widespread aliment and underlying condition in many chronic diseases. Alex holds an MBA from the State University of New York at Albany and an executive MBA from the Lorange Institute of Business Zurich.